Mononuclear cells from patients recovered from cutaneous leishmaniasis respond to Leishmania major amastigote class I nuclease with a predominant Th1‐like response
暂无分享,去创建一个
[1] N. Reiner,et al. Molecular characterization of a novel amastigote stage specific Class I nuclease from Leishmania major. , 2004, International journal for parasitology.
[2] K. Campbell,et al. DNA Immunization with the Gene Encoding P4 Nuclease of Leishmania amazonensis Protects Mice against Cutaneous Leishmaniasis , 2003, Infection and Immunity.
[3] S. Croft,et al. Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs. , 2003, Trends in parasitology.
[4] D. Mcmahon-Pratt,et al. Perforin and Gamma Interferon Are Critical CD8+ T-Cell-Mediated Responses in Vaccine-Induced Immunity against Leishmania amazonensis Infection , 2003, Infection and Immunity.
[5] D. Mcmahon-Pratt,et al. Evaluation of amastigote reactive cells in human cutaneous leishmaniasis caused by Leishmania aethiopica , 2003, Clinical and experimental immunology.
[6] A. Khamesipour,et al. The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis. , 2002, Vaccine.
[7] C. Auriault,et al. IL-10 leads to a higher parasite persistence in a resistant mouse model of Leishmania major infection. , 2002, Parasitology international.
[8] D. Sacks,et al. The immunology of susceptibility and resistance to Leishmania major in mice , 2002, Nature Reviews Immunology.
[9] Y. Belkaid,et al. CD8+ T Cells Are Required for Primary Immunity in C57BL/6 Mice Following Low-Dose, Intradermal Challenge with Leishmania major , 2002, The Journal of Immunology.
[10] A. Debrabant,et al. Developmentally regulated expression of a cell surface class I nuclease in Leishmania mexicana. , 2002, International journal for parasitology.
[11] S. Coutinho,et al. T-Cell-Mediated Immune Responses in Patients with Cutaneous or Mucosal Leishmaniasis: Long-Term Evaluation after Therapy , 2002, Clinical and Vaccine Immunology.
[12] Y. Belkaid,et al. The Role of Interleukin (IL)-10 in the Persistence of Leishmania major in the Skin after Healing and the Therapeutic Potential of Anti–IL-10 Receptor Antibody for Sterile Cure , 2001, The Journal of experimental medicine.
[13] D. Wolday,et al. Induction and abrogation of LACK reactive cells in the evolution of human leishmaniasis , 2001, Clinical and experimental immunology.
[14] Y. Belkaid,et al. The Potency and Durability of DNA- and Protein-Based Vaccines Against Leishmania major Evaluated Using Low-Dose, Intradermal Challenge , 2001, The Journal of Immunology.
[15] R. Coffman,et al. Interleukin-10 and the interleukin-10 receptor. , 2001, Annual review of immunology.
[16] S. Kar,et al. The immunologically protective P-4 antigen of Leishmania amastigotes. A developmentally regulated single strand-specific nuclease associated with the endoplasmic reticulum. , 2000, The Journal of biological chemistry.
[17] S. Jeronimo,et al. IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. , 2000, Cytokine.
[18] F. Koning,et al. A Leishmania homologue of receptors for activated C-kinase (LACK) induces both interferon-gamma and interleukin-10 in natural killer cells of healthy blood donors. , 2000, The Journal of infectious diseases.
[19] John T. Chang,et al. Requirements for the Maintenance of Th1 Immunity In Vivo Following DNA Vaccination: A Potential Immunoregulatory Role for CD8+ T Cells , 2000, The Journal of Immunology.
[20] E. Ghedin,et al. Dissection of the Functional Domains of theLeishmania Surface Membrane 3′-Nucleotidase/Nuclease, a Unique Member of the Class I Nuclease Family* , 2000, The Journal of Biological Chemistry.
[21] R. Coffman,et al. Experimental Leishmania major infection in mice: role of IL‐10 , 1999, Parasite immunology.
[22] S. Gurunathan,et al. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection , 1998, Nature Medicine.
[23] S. Reed,et al. Human and Murine Immune Responses to a NovelLeishmania major Recombinant Protein Encoded by Members of a Multicopy Gene Family , 1998, Infection and Immunity.
[24] D. Mcmahon-Pratt,et al. Leishmania pifanoi Amastigote Antigen P-4: Epitopes Involved in T-Cell Responsiveness in Human Cutaneous Leishmaniasis , 1998, Infection and Immunity.
[25] S. Reed,et al. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. , 1996, Journal of immunology.
[26] D. Mcmahon-Pratt,et al. T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure. , 1996, Experimental parasitology.
[27] J. Streit,et al. Visceral Leishmaniasis , 2011 .
[28] A. Satoskar,et al. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection , 1995, Infection and immunity.
[29] T. Baldwin,et al. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response , 1995, Infection and immunity.
[30] D. Mcmahon-Pratt,et al. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect Immun 63 , 1995 .
[31] A. Debrabant,et al. Isolation and characterization of the gene encoding the surface membrane 3'-nucleotidase/nuclease of Leishmania donovani. , 1995, Molecular and biochemical parasitology.
[32] G. Trinchieri,et al. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12 , 1995, The Journal of experimental medicine.
[33] P. Romero,et al. Leishmania major infection in mice primes for specific major histocompatibility complex class I‐restricted CD8+ cytotoxic T cell responses , 1994, European journal of immunology.
[34] J. Louis,et al. Expansion of gamma interferon-producing CD8+ T cells following secondary infection of mice immune to Leishmania major , 1994, Infection and immunity.
[35] T. Theander,et al. Dichotomy of the human T cell response to Leishmania antigens. I. Th1‐like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis , 1994, Clinical and experimental immunology.
[36] H. Akuffo,et al. Natural and acquired resistance to Leishmania: cellular activation by Leishmania aethiopica of mononuclear cells from unexposed individuals is through the stimulation of natural killer (NK) cells , 1993, Clinical and experimental immunology.
[37] R. Pearson,et al. Potential role for interleukin-10 in the immunosuppression associated with kala azar. , 1993, The Journal of clinical investigation.
[38] A. Kharazmi,et al. Evaluation of the efficacy of Iran leishmanin and comparison with leishmanins from Wellcome (UK) and Roma (Italy) in cured cutaneous leishmaniasis patients. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[39] J. Louis,et al. Gamma interferon response in secondary Leishmania major infection: role of CD8+ T cells , 1993, Infection and immunity.
[40] P. Scott,et al. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis , 1993, Infection and immunity.
[41] Mohamed,et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. , 1993, The Journal of clinical investigation.
[42] G. O. Gbenle,et al. Purification and properties of 3'-nucleotidase of Leishmania donovani. , 1992, The Biochemical journal.
[43] P. Melby. Experimental leishmaniasis in humans: review. , 1991, Reviews of infectious diseases.
[44] J. Sacci,et al. Purification and characterization of the 3'-nucleotidase/nuclease from promastigotes of Leishmania donovani. , 1991, Molecular and biochemical parasitology.
[45] R. Locksley,et al. Helper T-cell subsets in mouse leishmaniasis: induction, expansion and effector function. , 1991, Immunology today.
[46] T. Neubert,et al. An inducible 3'-nucleotidase/nuclease from the trypanosomatid Crithidia luciliae. Purification and characterization. , 1990, The Journal of biological chemistry.
[47] E. Handman,et al. Leishmania major: production of recombinant gp63, its antigenicity and immunogenicity in mice. , 1990, Experimental parasitology.
[48] L. Schnur,et al. Delayed-type hypersensitivity and lymphocyte proliferation in response to Leishmania major infection in a group of children in Jericho. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[49] D. Mcmahon-Pratt,et al. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection , 1988, Infection and immunity.
[50] A. Goldstein,et al. Purification and properties , 1975 .
[51] D. Heyneman. Immunology of leishmaniasis. , 1971, Bulletin of the World Health Organization.